Cosmos Health Pockets 10-Year Manufacturing Deal With Provident Pharmaceuticals
Take Stock Of The Week Ahead

Get all the latest Share Market trends and news to set you up for the week ahead.

Zinger Key Points
  • Cosmos Health signs 10-year deal with Provident to produce four drugs, totaling 8 million packs over the contract duration.
  • CEO Greg Siokas highlights growth potential, focusing on stable, high-margin cash flows from expanded contract manufacturing.

Cosmos Health Inc. COSM shares are trading slightly lower on Friday.

The company revealed that its wholly owned subsidiary, Cana Laboratories, has entered into a ten-year contract manufacturing agreement with Provident Pharmaceuticals, a specialty pharmaceutical company.

This partnership will focus on producing four pharmaceutical products, including Miorelique, BE Union F.C., and two variations of Certorun, with an annual production target of 800,000 packs, totaling 8 million packs over the agreement’s duration.

The agreement encompasses the production of Miorelique, an oral Baclofen solution with an annual production volume of 200,000 packs. Miorelique serves as a muscle relaxant to treat spasticity, following the reference drug, Lioresal.

Also Read: Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock

Another key product in the deal is BE Union F.C. tablets, formulated with a vitamin B-complex blend, designed for nerve health and neuropathy support. These tablets will have a production volume of 400,000 packs per year.

Additionally, the contract covers Certorun, a Sertraline-based antidepressant, available in both 50 mg and 100 mg formulations, targeting a combined annual production of 200,000 packs.

Greg Siokas, CEO of Cosmos Health, expressed confidence in the partnership, emphasizing how it will accelerate Cana’s growth.

“We are very pleased to expand our already successful collaboration with Provident, further accelerating the growth of our contract manufacturing business at Cana’s state-of-the-art facilities,” Siokas said.

“These additional orders from Provident underscore our capabilities, and we remain well-positioned to accommodate further contract manufacturing opportunities that contribute to stable, long-term, high-margin cash flows for Cosmos,” the CEO added. 

According to Benzinga Pro, COSM stock has lost over 11% in the past year.

Price Action: COSM shares are trading lower by 1.23% to $0.7136 at last check Friday.

See Also: 

Photo by MargJohnsonVA via Shutterstock.

Don't miss a beat on the share market. Get real-time updates on top stock movers and trading ideas on Benzinga India Telegram channel.

Comments
Loading...